Technology Dealmaking Shifts as Markets Evolve

In developing news, homeFundingHoudini Bio emerges from stealth with €1.7 million to tackle DNA silencing… HomeFundingHoudini Bio emerges from stealth with €1.7 million to tackle DNA silencing…FundingUK-Startups Houdini Bio emerges from stealth with €1.7 million to tackle DNA silencing in gene therapies By David Cendon Garcia June 19, 2026 Share FacebookTwitterWhatsAppLinkedin British BioTech startup Houdini Bio has exited out of stealth today with approximately €1.7 million (£1.5 million) in pre-Seed funding in order to validate its DNA sequence deThe round was led by SCVC (the venture arm of Science Creates), with participation from Deep Science Ventures and the University of Cambridge (Cambridge Enterprise VC).Key players involved: Partners Group, GI Partners This development has significant implications for the industry, potentially influencing competitive dynamics, investment patterns, and strategic priorities across the sector. “The industry has made incredible strides, proving genetic medicines can cure previously untreatable diseases, but cellular machinery still rejects these therapies, limiting long term effectiveness and forcing costly, unsafe doses,” says Jonathan Cohen-Gold, CEO and co-founder of Houdini Bio. Market ImplicationsForward-Looking IndicatorsContinued consolidation expected in the sectorIncreasing focus on digital transformation and innovationGrowing importance of ESG considerations Expert Commentary Looking AheadFor complete details on this development, refer to the original report from EU-Startups. Frequently Asked Questions